Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
New Oncolines publication in Cancers
IL4I1 in ascites as a marker in high-grade serous ovarian cancer The emergence [...]
Oncolines Team Joins Symeres
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities Nijmegen, [...]
New in Frontiers in Oncology: comparative profiling study of newly approved kinase inhibitors
In the last two decades, nearly 60 small molecule kinase inhibitors have been approved [...]
